About GlycoMimetics (NASDAQ:GLYC)
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:GLYC
- CUSIP: N/A
- Web: www.glycomimetics.com
- Current Ratio: 17.44%
- Quick Ratio: 17.44%
Sales & Book Value:
- Annual Sales: $20,000.00
- Price / Sales: 21,067.59
- Book Value: $1.53 per share
- Price / Book: 8.02
- Trailing EPS: ($1.24)
- Net Income: ($31,800,000.00)
- Return on Equity: -44.45%
- Return on Assets: -40.83%
- Employees: 42
- Outstanding Shares: 34,340,000
Frequently Asked Questions for GlycoMimetics (NASDAQ:GLYC)
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.04. View GlycoMimetics' Earnings History.
Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?
6 Wall Street analysts have issued 12 month target prices for GlycoMimetics' stock. Their forecasts range from $12.00 to $25.00. On average, they anticipate GlycoMimetics' stock price to reach $18.20 in the next twelve months. View Analyst Ratings for GlycoMimetics.
What are Wall Street analysts saying about GlycoMimetics stock?
Here are some recent quotes from research analysts about GlycoMimetics stock:
- 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (11/13/2017)
- 2. Cowen and Company analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), Revance Therapeutics (RVNC), CytomX Therapeutics (CTMX), Raptor Pharmaceutical Corp (RPTP), La Jolla Pharmaceutical Company (LJPC), Five Prime Therapeutics (FPRX), Akebia Therapeutics (AKBA), Alder BioPharmaceuticals (ALDR), MacroGenics (MGNX), Aclaris Therapeutics (ACRS), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Aduro Biotech (ADRO), PTC Therapeutics (PTCT) and ZIOPHARM Oncology (ZIOP).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- M. James E. Barrett Ph.D., Independent Chairman of the Board (Age 74)
- Rachel K. King, President, Chief Executive Officer, Co-Founder, Director (Age 57)
- John Magnani Ph.D., Co-Founder, Senior Vice President, Chief Scientific Officer, Director (Age 64)
- Brian Hahn, Chief Financial Officer (Age 42)
- Helen M. Thackray M.D., , Senior Vice President - Clinical Development, Chief Medical Officer (Age 47)
- Patricia S. Andrews, Director
- Mark Alan Goldberg M.D., Independent Director (Age 62)
- Daniel M. Junius, Independent Director (Age 64)
- Scott Koenig M.D., Ph.D., Independent Director (Age 64)
- Timothy R. Pearson, Independent Director (Age 49)
Who owns GlycoMimetics stock?
GlycoMimetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (1.42%), EAM Investors LLC (1.13%), Alyeska Investment Group L.P. (1.05%), Columbus Circle Investors (0.62%), Citadel Advisors LLC (0.18%) and TD Asset Management Inc. (0.08%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.
Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?
Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?
GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Citadel Advisors LLC, EAM Investors LLC, Fox Run Management L.L.C., Alyeska Investment Group L.P. and Dynamic Technology Lab Private Ltd. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.
How do I buy GlycoMimetics stock?
Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GlycoMimetics stock can currently be purchased for approximately $12.27.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $421.33 million and generates $20,000.00 in revenue each year. The biotechnology company earns ($31,800,000.00) in net income (profit) each year or ($1.24) on an earnings per share basis. GlycoMimetics employs 42 workers across the globe.
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for GlycoMimetics (NASDAQ:GLYC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$18.20 (48.33% upside)|
Consensus Price Target History for GlycoMimetics (NASDAQ:GLYC)
Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/26/2017||Jefferies Group LLC||Reiterated Rating||Buy||$16.00||N/A|
|10/23/2017||Roth Capital||Initiated Coverage||Buy||$25.00||N/A|
|10/4/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$21.00||N/A|
|8/4/2017||Stifel Nicolaus||Reiterated Rating||Buy||$13.00 -> $17.00||Low|
|5/28/2017||Cowen and Company||Reiterated Rating||Outperform||Low|
|5/19/2017||Canaccord Genuity||Reiterated Rating||Buy||$12.00||High|
Earnings History and Estimates Chart for GlycoMimetics (NASDAQ:GLYC)
Earnings History by Quarter for GlycoMimetics (NASDAQ GLYC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2017||Q4 2016||($0.35)||($0.36)||$4.50 million||View||N/A|
|8/6/2015||Q2 2015||($0.40)||$0.51||$20.04 million||View||N/A|
|7/31/2014||Q2 2014||$0.24||$0.39||$9.08 million||$15.03 million||View||N/A|
|3/31/2014||($2.17)||($2.80)||$9.65 million||$0.08 million||View||N/A|
Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
2017 EPS Consensus Estimate: ($1.32)
2018 EPS Consensus Estimate: ($0.43)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GlycoMimetics (NASDAQ GLYC)
Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 88.32%
Insider Trades by Quarter for GlycoMimetics (NASDAQ GLYC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/18/2017||Helen M Thackray||SVP||Sell||2,000||$13.00||$26,000.00|| |
|5/25/2017||Helen M Thackray||SVP||Sell||2,000||$15.57||$31,140.00|| |
|5/19/2017||Helen M Thackray||SVP||Sell||2,000||$12.14||$24,280.00|| |
|12/20/2016||Daniel M. Junius||Director||Buy||5,000||$6.01||$30,050.00|| |
|10/3/2016||Helen M Thackray||VP||Sell||4,000||$7.00||$28,000.00|| |
|7/20/2016||Helen M Thackray||VP||Sell||2,000||$8.00||$16,000.00|| |
|7/6/2016||Helen M Thackray||CMO||Sell||22,000||$7.00||$154,000.00|| |
|3/4/2016||Mark Alan Goldberg||Director||Buy||10,397||$4.77||$49,593.69|| |
|12/22/2014||Michael A Henos||Director||Sell||21,257||$8.52||$181,109.64|| |
|12/17/2014||Michael A Henos||Director||Sell||6,725||$8.97||$60,323.25|| |
|12/15/2014||Michael A Henos||Director||Sell||1,604||$8.98||$14,403.92|| |
|6/13/2014||Michael A Henos||Director||Buy||11,000||$6.39||$70,290.00|| |
|1/15/2014||Enterprise Associates 13 L New||Major Shareholder||Buy||512,500||$8.00||$4,100,000.00|| |
|1/15/2014||M James Barrett||Director||Buy||1,000,000||$8.00||$8,000,000.00|| |
Latest Headlines for GlycoMimetics (NASDAQ GLYC)
|Selectin Inhibition Justifies GlycoMimetics Investment|
seekingalpha.com - November 16 at 2:46 PM
|GlycoMimetics, Inc. (GLYC) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 13 at 11:46 PM
|GlycoMimetics, Inc. (GLYC) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - November 13 at 9:34 PM
|SunTrust Banks Comments on GlycoMimetics, Inc.'s Q1 2018 Earnings (GLYC)|
www.americanbankingnews.com - November 13 at 6:00 AM
|Jefferies Group Comments on GlycoMimetics, Inc.'s FY2017 Earnings (GLYC)|
www.americanbankingnews.com - November 13 at 3:36 AM
|Analyzing GlycoMimetics (GLYC) and Its Peers|
www.americanbankingnews.com - November 12 at 11:54 PM
|GlycoMimetics to Present at Upcoming Healthcare Investor Conferences - Business Wire (press release)|
www.businesswire.com - November 11 at 6:59 AM
|GlycoMimetics, Inc. (GLYC) to Post Q1 2018 Earnings of ($0.25) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - November 10 at 10:50 AM
|GlycoMimetics, Inc. (GLYC) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS|
www.americanbankingnews.com - November 9 at 6:33 PM
|GlycoMimetics Reports Program Updates and Third Quarter 2017 Results - Business Wire (press release)|
www.businesswire.com - November 9 at 6:09 AM
|Edited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMT|
finance.yahoo.com - November 9 at 6:09 AM
|GlycoMimetics, Inc. to Host Earnings Call|
finance.yahoo.com - November 8 at 8:05 AM
|GlycoMimetics Reports Program Updates and Third Quarter 2017 Results|
finance.yahoo.com - November 8 at 8:05 AM
|Why Earnings Season Could Be Great for GlycoMimetics (GLYC) - Nasdaq|
www.nasdaq.com - November 2 at 8:53 PM
|Why Earnings Season Could Be Great for GlycoMimetics (GLYC)|
finance.yahoo.com - November 2 at 8:53 PM
|GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting|
finance.yahoo.com - November 1 at 8:43 PM
|GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017|
finance.yahoo.com - November 1 at 8:43 PM
|GlycoMimetics, Inc. (GLYC) Rating Reiterated by Jefferies Group LLC|
www.americanbankingnews.com - October 26 at 2:44 PM
|GlycoMimetics, Inc. (GLYC) Coverage Initiated by Analysts at Roth Capital|
www.americanbankingnews.com - October 23 at 10:40 PM
|GlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - October 19 at 8:46 PM
|GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : October 17, 2017|
finance.yahoo.com - October 17 at 7:49 PM
|GlycoMimetics, Inc. (GLYC) Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - October 16 at 11:20 PM
|GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017|
finance.yahoo.com - October 16 at 3:48 PM
|Head-To-Head Contrast: GlycoMimetics (GLYC) versus Its Competitors|
www.americanbankingnews.com - October 16 at 2:10 AM
|GlycoMimetics, Inc. (GLYC) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - October 6 at 11:14 PM
|GlycoMimetics, Inc. (GLYC) Receives "Buy" Rating from SunTrust Banks, Inc.|
www.americanbankingnews.com - October 4 at 9:14 PM
|BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln|
www.reuters.com - September 28 at 8:29 PM
|GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher|
finance.yahoo.com - September 26 at 11:40 AM
|GlycoMimetics Inc (GLYC) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - September 24 at 8:34 PM
|GlycoMimetics, Inc. (GLYC) SVP Sells $26,000.00 in Stock|
www.americanbankingnews.com - September 18 at 8:10 PM
|GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017|
finance.yahoo.com - September 11 at 7:37 PM
|Can GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions?|
finance.yahoo.com - September 6 at 1:26 AM
|GlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference|
finance.yahoo.com - September 6 at 1:26 AM
|GlycoMimetics, Inc. (GLYC) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - August 30 at 8:36 PM
|GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 25, 2017|
finance.yahoo.com - August 26 at 3:21 AM
|Q3 2017 Earnings Forecast for GlycoMimetics, Inc. (NASDAQ:GLYC) Issued By SunTrust Banks|
www.americanbankingnews.com - August 9 at 8:08 AM
|GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017|
finance.yahoo.com - August 8 at 6:48 PM
|GlycoMimetics, Inc. (GLYC) Posts Earnings Results, Beats Expectations By $0.07 EPS|
www.americanbankingnews.com - August 5 at 9:56 PM
|GlycoMimetics, Inc. (NASDAQ:GLYC) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - August 5 at 8:56 PM
| Brokerages Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.37 EPS|
www.americanbankingnews.com - August 5 at 12:44 PM
|Stifel Nicolaus Reiterates Buy Rating for GlycoMimetics, Inc. (NASDAQ:GLYC)|
www.americanbankingnews.com - August 5 at 11:34 AM
|GlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : August 1, 2017|
finance.yahoo.com - August 1 at 7:41 PM
|GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017|
finance.yahoo.com - July 19 at 7:45 PM
|GlycoMimetics, Inc. (NASDAQ:GLYC) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - July 11 at 8:50 PM
|FDA Issues an Approval Not Seen in Almost 20 Years|
247wallst.com - July 8 at 11:07 AM
|BRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271|
www.reuters.com - July 6 at 8:59 PM
|GlycoMimetics to Receive European Patent for GMI-1271|
finance.yahoo.com - July 6 at 8:59 PM
|BRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO|
www.reuters.com - June 5 at 5:35 PM
|ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD|
www.rttnews.com - May 31 at 9:02 AM
|GlycoMimetics (GLYC) Says GMI-1271 Received EU Orphan Drug Designation for AML|
www.streetinsider.com - May 25 at 7:52 PM
GlycoMimetics (NASDAQ GLYC) Chart for Sunday, November, 19, 2017